NCT03166891View on ClinicalTrials.gov

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

March 20, 2019

Study Completion Date

March 20, 2019

Conditions
Ovarian Cancer
Interventions
DRUG

Chiauranib

Take 50mg orally once daily

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY